William Oh
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
William Oh
Jul 19, 2024, 12:31 |
Insight
Genetic Testing in Men With mCRPC
William Oh shared a post on LinkedIn about a recent paper by Pedro Barata et…
Feb 4, 2024, 11:46 |
Insight
William Oh: The $100 genome, marching to a $10 genome
William Oh, Chief Medical Officer at Prostate Cancer Foundation, recently shared on LinkedIn: "The $100…
Jan 22, 2024, 09:45 |
Insight
William Oh: For the first time, there will be more than 2 million new US cancer cases in 2024, led in men by prostate cancer
William Oh, Chief Medical Officer at the Prostate Cancer Foundation (PCF), shared on LinkedIn: "For…
Dec 2, 2023, 16:55 |
Insight
William Oh: Better biology and new targeted therapies is driving more benefit for patients, but there is still a long way to go
William Oh, Chief Medical Officer at the Prostate Cancer Foundation (PCF), shared on LinkedIn: "MSK-IMPACT…
Nov 26, 2023, 11:50 |
Blog
William Oh: The results of the largest cohort of over 17k men of European ancestry who underwent exome sequencing with aggressive prostate cancer
William Oh, Chief Medical Officer at Prostate Cancer Foundation, posted on LinkedIn: "Germline genetic testing is…
Oct 3, 2023, 17:22 |
Insight
William Oh: For men with aggressive prostate cancer, genetic testing can inform treatment decisions.
Quoting William Oh, Chief Medical Officer of Prostate Cancer Foundation, on LinkedIn: ''Germline exome sequencing…
Aug 6, 2023, 03:24 |
Blog
The more fit your heart and lungs, the less likely you were to die of prostate cancer - William Oh
Cardiorespiratory fitness (CRF) was associated with prostate cancer-specific mortality in a dose-dependent manner: the more…
All:
7
Posts:
1 - 100
Michael Douglas: The Untold Story of His Battle Against Cancer
Our commitment to seek all possible pathways to make BOT/BAL available to patients is unwavering: Steven O'Day, Agenus CMO
EMA Joins FDA: Osimerintib + Chemo Approved for EGFR-Mutated Lung Cancer
Kimryn Rathmell: Principles that have kept me going as a Physician Scientist
Amazing Results! President Lynn M. Schuchter on ASCO 2024
Facebook
RSS Feed
Twitter
Linkedin
Youtube